Thiogenesis Secures Key European Patent

Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.

Thiogenesis Therapeutics Corp has secured a key European patent for its innovative thiol compounds, enhancing its global intellectual property portfolio. The patent supports the company’s lead compound, TTI-0102, which aims to combat oxidative stress, a factor in chronic diseases like mitochondrial disorders and diabetes.

For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.